Clinical research of advanced non-small cell lung cancer patients treated with CIK cell combined with chemotherapy

Objective To observe the efficacy of CIK cells combined with chemotherapy for advanced non-small cell lung cancer,and to investigate patients' quality of life and toxicity of the treatment.Methods Totally 48 patients with advanced non-small cell lung cancer were randomly divided into two groups,the study group of 23 patients(TP+CIK cell immunotherapy program) and the control group of 25 patients(TP).Efficacy and toxicity were evaluated,and QLQ-LC13 scale used before and after treatment to assess the quality of life.Results The effictive rate of the study group was 39.1%,which was higher than that of the control group(36.0%,P0.05).The difference was not statistically significant;LC13 scale in the study group was also superior to that in the control group(P0.05);the main toxicities in the process of CIK cell infusion was fever.Conclusion CIK cells transfusion is safe.Combined with chemotherapy for advanced non-small cell lung cancer patients it can improve quality of life.The treatment is expected to be safe and effective.